Introduction
Heat stroke (HS) represents the severe end of a spectrum of heat-related illnesses. It is defined as an elevated core temperature, usually above 40°C, in association with central neurological dysfunction caused by hyperthermia. If the rate of heat production is greater than heat loss, then the body' s core temperature rises, leading to cellular damage and systemic inflammatory response syndrome (SIRS), and ultimately, multiorgan failure and death.
Two forms are recognised -classical and exertional. Classical HS tends to be seen during heatwaves, and often affects the elderly or very young, or patients with comorbidities. Exertional HS (EHS) develops during exercise or physical exertion, particularly in warmer weather, and therefore often affects younger, fitter people. In addition to the demographic differences, the complications of hyperkalaemia, acute renal failure, rhabdomyolysis and disseminated intravascular coagulation (DIC) are commonly seen in EHS, but less so in classical HS. 1 Otherwise, many of the features, including the pathophysiology, are thought to be similar. 2 Exertional heat stroke, the focus of this article, is increasingly recognised in marathon runners and endurance athletes. It is increasing in incidence and has significant shortand long-term morbidity and mortality if it is poorly managed. Even with timely treatment, patients are at risk of multi-organ failure, and long-term neurological and cognitive abnormalities and death. It is therefore important that it is recognised and treated early.
It was first described in 24 BC, concerning an Egyptian governor and his army, when 'the desert, the sun and the water, which had some peculiar nature, all caused his men great distress so that the larger part of the army perished. The malady proved to be unlike any of the common complaints but attacked the head and caused it to become parched, killing forthwith most of those who were attacked, but in the case of those who survived this stage, it descended to the legs, skipping all the intervening parts of the body and caused dire injury to them.' 3 While we now know it does affect 'the intervening parts of the body' and the treatment of 'olive oil and wine, both taken as a drink and used as an ointment' is now not recommended, the morbidity and mortality even today remain high.
Epidemiology
When treatment of classical HS is delayed, the mortality rate may be as high as 80%, however, with early diagnosis and immediate cooling, the mortality rate can be reduced to 10%. 4 Data on the incidence of EHS are unclear, but the US Army reported 994 hospitalisations with EHS between 1980 and 2002 5 and it is one of the three commonest causes of sudden deaths in athletes. 6 It is likely that that there are many unrecorded cases, in addition to those reported, who improve rapidly with prehospital treatment and do not require hospital admission. One of the authors (EW) was involved with treating six casualties from two road races of 10 and 13 miles. 7 All six were initially treated at the on-site medical centre and were actively cooled within minutes of their collapse. One of the patients returned to normal very rapidly and was discharged from the medical centre within a few hours. One patient presented with a reduced level of consciousness and required intubation and ventilation in an intensive care unit (ICU) but subsequently
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made a full recovery. The remaining four patients were admitted to the emergency department (ED) of the local hospital after initial treatment at the medical centre. All four were discharged from the ED within a few hours without the need for inpatient management. The authors have also been involved with 18 patients with EHS following a marathon, in which a total of 20,000 runners participated. All of these were treated within a few minutes of their collapse at the on-site medical centre. Five patients required in-patient treatment in the local hospital but all were discharged after a brief admission. The remaining patients improved rapidly enough to be discharged from the medical centre after only a few hours.
Heat stroke is rarer in women than men. This may be because of the decreased muscle bulk, or the protective effect of oestrogen, which is thought to reduce the inflammatory response or to improve the hypotension and hypoperfusion associated with HS. 8 The number of cases of EHS appears to be on the rise. This may be due in part to increasing numbers of athletes participating in endurance events each year. An estimated 25,000 runners completed a marathon in the United States during 1976; by 2000, this had grown to 353,000 and in 2009 to 467,000. 9 However, the incidence may also be rising; a large epidemiological study from the American military reported a rate of hospitalisation from EHS of 1.8 per 100,000 soldiers in 1981 compared with 14.5 per 100,000 in 2001, 10 an eight-fold increase. The reason for this is not clear.
Pathophysiology
While there are differences in epidemiology and the demographics of patients at risk of classical HS and EHS, the pathophysiology is probably common to both, suggesting that they represent two forms of the same disease. 2 Until recently, the morbidity and mortality in HS was thought to be purely due to the thermal damage. However, it is now recognised to be due to a combination of cellular damage from the heat, coagulopathy and the SIRS following damage to the gut and other organs exacerbated by regional variation in blood flow. Multi-organ failure is the ultimate cause of mortality.
Splanchnic blood flow falls in an attempt to maintain blood pressure. Gastro-intestinal ischaemia may allow translocation of gut bacteria into the systemic circulation, 11 which may be the precipitating trigger for SIRS. The liver is important for endotoxin clearance, with liver dysfunction associated with higher circulating endotoxin levels. 2 However, the liver may itself be damaged from HS. In one study, there was an improvement in survival following a reduction in endotoxin load with anti-lipopolysaccharide. 12 Cerebral blood flow also falls, which may partly account for neurological abnormalities. 13 DIC is common in heat stroke. It is initiated by thermal injury to the vascular endothelium, and is made worse by circulating cytokines and endotoxaemia. When the core temperature reaches 43-44°C, platelet aggregation occurs which may be irreversible, even when the patient' s temperature returns to normal. 14 Cytokines modulate the immune system. Increased circulating levels of various cytokines (for example, interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-10, IL-12, interferon-γ, tumour necrosis factor (TNF-α)) are often seen during or immediately after an episode of heat stroke, or following cooling. 2 Their role is not completely defined. High circulating levels are seen in patients with a higher risk of morbidity and mortality, suggesting that they may worsen outcome. However, in one study, maximal concentrations of IL-1β, IL-6 and others occurred following cooling, 15 suggesting that at least some of these cytokines may have protective effects. Similarly, the group of heat-shock proteins appear to confer some protection against hyperthermia, with higher levels of one subtype (HSP72) associated with improved survival. 16 HS is therefore a pro-inflammatory and pro-coagulant disease. Steroids, 17 mannitol, 17 and recombinant activated protein C 18, 19 have all been studied as putative treatments, and have shown benefit in trials, but none are currently recommended for clinical practice. Non-steroidal antiinflammatory drugs have not been extensively studied and in any case the risk of acute kidney injury in EHS is high. Aspirin may have beneficial effects in survival in an animal model, 20 and may reduce platelet aggregation, which is seen as part of the coagulopathy of HS. 14 However, neither aspirin nor paracetamol has any proven benefit in humans and neither is currently widely recommended. 21 They may not be expected to have a significant effect; antipyretics interrupt the change in the hypothalamic set point caused by pyrogenic mediators. While there is some evidence of pyrogenic cytokines in HS, 22 much of the pyrexia is thought to be excessive production of heat rather than disruption of hypothalamic homeostasis.
Risk factors
Traditionally, EHS has been associated with exercise in warm weather. However, a recent case series has suggested that athletes exercising in cool weather may be at risk as well, 7 so clinicians need to be alert to the diagnosis. EHS can also affect military personnel in warmer weather and occupations exposed to heat, for example firemen.
A variety of medical conditions ( Table 1) and medications ( Table 2) have been identified which may increase the risk of HS. The putative medications may work through a variety of mechanisms. These include: promoting fluid loss, interfering with blood flow, increasing core temperature per se, or interfering with mechanisms of heat loss, for example, by reducing sweat production.
Review articles
Aetiology
Certain individuals appear to be at higher risk of developing EHS. There may be a genetic predisposition. No genes have yet been identified in EHS, but there are genetic, clinical and biochemical similarities with malignant hyperthermia (MH).
Around two thirds of patients with MH show evidence of mutations in the type 1 ryanodine receptor (RyR1). The ryanodine receptor is involved with calcium release from the sarcoplasmic reticulum of skeletal muscle, and it is important in excitation-contraction coupling. 23 More recent work has focussed on calsequestrin. Calsequestrin is a protein of the sarcoplasmic reticulum which binds calcium and affects ryanodine receptor function. A mouse knockout model lacking skeletal muscle calsequestrin has recently been developed. 24 In mice lacking this gene, both hyperthermia and exposure to halothane increased mortality, suggesting that an abnormal calsequestrin phenotype or abnormal function may be responsible for some cases of both MH and EHS. 24 There are also some similarities in the biochemical changes seen in MH and EHS patients during the acute phases. Contraction of EHS muscle and MH muscle appear to show similar characteristics after exposure to halothane and caffeine. 25 Intracellular acidosis has also been shown to develop early in EHS and MH during exercise. This is thought to be due to an abnormally large cytosolic calcium concentration activating excessive glycogenolysis to meet energy demand. In addition, the histological abnormalities seen in muscle taken from MH-and EHS-susceptible patients are similar and include mitochondrial myopathy, denervation, and atrophy of type II fibres. 26 Recent case reports suggest that EHS and MH may occur in the same individuals, raising the possibility that they are analogous diseases or share a similar underlying abnormality. Following an episode of EHS, two patients and their families underwent MH testing. Muscle samples from both patients showed an abnormal response to halothane. Muscle from the father of one patient had an abnormal response to halothane, and that from the father of the second patient had an abnormal response to ryanodine. 27 Similarly, a 12-year-old boy developed MH during surgery to reduce a humeral fracture. Following a game of football eight months later, he developed what was thought to be EHS, from which he died. 28 
Clinical features
Endurance athletes requiring medical treatment may collapse for a variety of reasons, ranging from a benign loss of postural tone at cessation of exercise, to serious electrolyte imbalances, as well as exertional heat illness. 29 These conditions may coexist. Collapsed athletes may show normal, low or high sodium and potassium plasma levels, and they may be dehydrated, over-hydrated or euvolaemic. Fluid and electrolyte management therefore depends on clinical assessment and plasma electrolyte measurement. Suxamethonium is generally avoided because of the risk of hyperkalaemia and the association with MH. Guidance given to athletes has changed recently as previous advice to drink liberally during sport has been associated with both hyper-and hypo-natraemia. The current advice is to drink only according to thirst. 30 This may be safer and reduce the incidence of electrolyte disturbance after endurance events (Walter EJ, unpublished data, 2011).
Preventing and avoiding EHS is important, for example, by acclimatising, only exercising when feeling well and avoiding open spaces in warm conditions. Some events recommend running with a partner and being compulsorily removed from events if athletes show signs of disorientation or confusion.
Patients with HS will present with confusion and disorientation, or drowsiness, or coma. This is probably due to a combination of increased cerebral metabolic rate, a reduction in cerebral blood flow and an increase in bloodbrain barrier permeability allowing endotoxins and pathogens to enter the brain. 2, 11 Patients are at risk of cerebral oedema. Airway protection and control of seizures and agitation may be required.
Patients are often tachycardiac and hypotensive from a combination of hypovolaemia and vasodilation. An increase in nitric oxide production may account for this. 31 Patients with HS are often paradoxically peripherally vasoconstricted and their peripheral temperature is therefore falsely reassuring; a core temperature measurement is therefore required and should be taken as soon as possible. Conversely, patients with heat exhaustion, rather than heat stroke, tend to be peripherally vasodilated. 32 Doppler studies of these patients tend to reflect a hyperdynamic circulation with a high cardiac output. 32 The electrocardiogram may show a variety of abnormalities, including conduction defects, QT and ST changes, and T-wave abnormalities. 33 In addition, cardiac dysfunction and associated pulmonary oedema have also been described. 34, 35 Acute kidney injury (AKI) is common, with military data suggesting that it affects around one sixth of patients. 10 Rhabdomyolysis following a marathon and following exercise generally is well described, but often does not progress to AKI. 36 In addition to rhabdomyolysis, volume depletion, DIC and alterations in circulating vasoactive mediators are also implicated in the development of AKI. Renal replacement therapy may be required which may have additional benefits of reducing the hyper-pyrexia, removing the metabolites of muscle breakdown and modulating the SIRS response. Hepatic injury is often seen, which may progress to fulminant liver failure and may be severe enough to require transplantation. 37 Liver failure may worsen the endotoxaemia and may cause hypo-or hyper-glycaemia. Lactic acidosis is common, from liver dysfunction, poor organ perfusion, and from the exercise itself.
Review articles
Immediate management
Currently, the only recommended treatment for EHS is rapid reduction of temperature and supportive treatment. Current guidelines stress the need for reducing the core temperature as quickly as possible. Treatment should start within minutes of diagnosis, ideally at the site of the collapse prior to transporting the casualty. One case series found a trend towards improved survival in patients cooled to a core temperature below 38.9°C within 60 minutes. 38 Patients often appear to return to normal within minutes given prompt treatment.
Various methods of cooling have been studied; a recent systematic review 39 suggests that immersion in cold water and cooling by conduction appear to be the most efficient for reducing body temperature. When ice-water immersion is not possible, continual dousing with water combined with fanning the patient is an alternative method. There is a risk that patients become hypothermic during such aggressive cooling, and 38.6°C has been suggested as a limit to active cooling in order to avoid this. 40 Rectal temperature measurement appears to be the most accurate and is the only recommended method in the field. Other methods, including oral, axillary, aural, temporal, and forehead temperatures are significantly different from rectal temperature, and may under-read by over 2°C. 41 Oesophageal temperature measurement may be accurate.
Antipyretics, for example, aspirin and paracetamol have not been shown to confer benefit. Dantrolene is standard treatment in the management of MH and may increase the rate of cooling in EHS, 42 but its use is not routinely recommended in heat illness. 42, 43 
Long-term complications
Even if patients survive the initial episode, HS is associated with significant long-term morbidity and mortality. Neurocognitive dysfunction following HS is well recognised, and may be caused by a combination of thermal damage, electrolyte and osmolar imbalance. The cognitive dysfunction can vary from mild deficits in attention, memory and personality, to severe global dementia. 44 Neurological deficits including paraparesis and cerebellar dysfunction have been described and may persist after the acute episode. 45, 46 Following the 2003 heat wave in France, patients reported a significant reduction in functional status persisting up to two years after the acute event. 47 Survivors of an episode of HS have been shown to experience a 40% increase in mortality from cardiovascular, kidney, and liver failure, even many years after the event. 48 Unfortunately, patients at risk are not necessarily detected by standard laboratory testing, and clinicians and patients should be aware of the long-term risks and effects of an episode of HS. In addition, patients may not be able to adapt to heat as well in the future, putting them at risk of a further episode of heat illness. 49 Patients may benefit from being tested for heat intolerance, if a facility exists, to guide future exercise and participation in sport.
Return-to-play considerations
After an episode of EHS, the American Inter-Association Task Force on Exertional Heat Illnesses advises athletes to avoid all exercise for one week and until they are asymptomatic and all laboratory tests are normal. After that, return to exercise should be gradual, and under the guidance of their sports physician. No such guidelines exist currently in the UK, but a careful, gradual return to exercise would seem sensible.
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